Home | Contact us | Site map | Careers | Q&A | Advantages of Québec |
  SGF Profile  
  Investment Groups  
  Our Investments  
  Documentation Center  
By investment groups
By companies
By regions of Québec

By investment groups


Mines, Materials, Energy, Environment 

Forest Products 

Life Sciences 

Information and Communication Technologies 




Warnex is a Canadian biotechnology company listed on the Toronto Stock Exchange (TSX WNX). The company is devoted to protecting public health by providing advanced diagnostic products and science-based services to the agri-food, pharmaceutical and healthcare sectors.

This two-pronged approach enables Warnex to generate a solid base of service-driven revenue, while benefiting from the high growth opportunity deriving from its promising pathogen detection technology.

The specialized laboratory services offered at Warnex includes the following services.

  • Warnex Analytical Services provides traditional chemistry, microbiology, chromatography and stability testing, as well as method development and validation, to clients in the pharmaceutical and biotechnology industries.
  • Warnex Bioanalytical Services conducts bioavailability and bioequivalence studies for clinical trials, and performs contract R&D for clients in the pharmaceutical and biotechnology industries. 
  • Warnex Medical Laboratories provides specialized medical laboratory testing, including the Prenatest® prenatal screening test for Down syndrome (trisomy 21), trisomy 18 and other chromosomal anomalies.

The Warnex™ Rapid Pathogen Detection System assesses the presence of pathogenic contamination of a food product by specifically identifying the DNA signature of a pathogen. As the DNA signature of each pathogen is unique, this identification is highly specific and accurate. The system allows for the simultaneous detection of multiple pathogens and processing of samples within 3 to 48 hours, a significant improvement over traditional microbiology tests that currently require 5 to 7 days.

SGF participation: 25%


Home  |  Legal Notice  |  Corporate Policies  | 

 Copyright © SGF 2009